leadf
logo-loader
viewScancell Holdings PLC

Scancell inks research collaboration deal with European biopharma BioNTech

The research collaboration will combine Scancell’s Moditope immunotherapy platform and BioNTech’s platform technology for high-throughput cloning and characterisation of naturally selected T cell receptors

cancer cells under a microscope
BioNTech recently raised US$270mln as part of a Series A funding

Cancer immunotherapy specialist Scancell Holdings Plc (LON:SCLP) has entered into a research collaboration agreement with European biopharma BioNTech as the two look to develop innovative T-cell therapies for the treatment of cancer.

The research collaboration will combine Scancell’s Moditope immunotherapy platform and BioNTech’s platform technology for high-throughput cloning and characterisation of naturally selected T-cell receptors.

READ: Scancell soars as it confirms Cancer Research UK to fund and sponsor SCIB2 clinical trial

Moditope is a new class of potentially potent immunotherapy agents which stimulate the production of killer CD4+ T cells that induce anti-tumour activity without toxicity.

To get a bit scientific, Moditope stimulates the production of the CD4+ T cells using tumour-associated peptide epitopes which allow the activated T cells to seek out and kill tumour cells that would otherwise have been hidden from the immune system.

Once the initial studies have been completed, BioNTech will have the exclusive option to enter into a licence agreement for the development of cell receptor based therapeutics that are specific to Scancell’s Modi-1 epitopes.

‘Great potential’

“We are delighted to be working with BioNTech, one of Europe's new immuno-oncology power-houses, to investigate the development of targeted immunotherapies for the treatment of cancer,” Scancell’s chief scientific officer Lindy Durrant.

READ: Scancell on the lookout for partners after year of “significant progress”

“Pre-clinical data from our Moditope platform has shown unprecedented anti-tumour effects can be delivered without the need for checkpoint inhibition.

“We believe that this, combined with BioNTech's engineered T cells specific to Moditope epitopes, could have great potential as a novel immunotherapy.”

Quick facts: Scancell Holdings PLC

Price: 15 GBX

LSE:SCLP
Market: LSE
Market Cap: £108.33 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Scancell Holdings PLC named herein, including the promotion by the Company of Scancell Holdings PLC in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Scancell to raise up to £8mln to develop its three main drug candidates

Cliff Holloway, chief executive at Scancell Holdings Plc (LONSCLP), tells Proactive Investors they're raising up to £8mln through a placing and open offer – cash that will be used develop their three main drug candidates. A placing and subscription at 12 pence a share will account for...

on 18/4/18

2 min read